LPA receptor antagonists and uses thereof
Granted: May 14, 2024
Patent Number:
11980609
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (TLD), or chronic kidney disease (CKD).
Inhibitors of peptidylarginine deiminases
Granted: May 7, 2024
Patent Number:
11976083
The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
Diacylglycerol kinase modulating compounds
Granted: May 7, 2024
Patent Number:
11976072
The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases
Granted: May 7, 2024
Patent Number:
11976071
The present disclosure provides bifunctional compounds of Formula (I), and pharmaceutically acceptable salts, isotopic forms, isolated stereoisomers, or mixtures of stereoisomers thereof, as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Granted: May 7, 2024
Patent Number:
11975017
The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.
Remdesivir treatment methods
Granted: May 7, 2024
Patent Number:
11975012
Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
Phospholipid compounds and uses thereof
Granted: April 23, 2024
Patent Number:
11963967
Compounds and methods of using said compounds, alone or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
Combination therapy comprising an ACC inhibitor
Granted: April 23, 2024
Patent Number:
11963961
The present disclosure provides methods and compositions for treating, stabilizing or lessening the severity or progression of a non-alcoholic fatty liver disease.
Combination MCL-1 inhibitors with anti-cancer agents
Granted: April 16, 2024
Patent Number:
11957693
The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.
Capsid inhibitors for the treatment of HIV
Granted: April 2, 2024
Patent Number:
11944611
The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
1?-cyano nucleoside analogs and uses thereof
Granted: March 26, 2024
Patent Number:
11939347
Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
LPA receptor antagonists and uses thereof
Granted: March 26, 2024
Patent Number:
11939318
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
Pharmaceutical package
Granted: March 26, 2024
Patent Number:
D1019381
Diacylglycerol kinase modulating compounds
Granted: March 19, 2024
Patent Number:
11932634
The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
Combination MCL-1 inhibitors with anti-body drug conjugates
Granted: March 19, 2024
Patent Number:
11931424
The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.
Compounds and methods for treatment of viral infections
Granted: March 12, 2024
Patent Number:
11926645
Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
Diacylglyercol kinase modulating compounds
Granted: March 12, 2024
Patent Number:
11926628
The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
Substituted 6-azabenzimidazole compounds
Granted: March 12, 2024
Patent Number:
11925631
The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
Pharmaceutical package
Granted: March 5, 2024
Patent Number:
D1016608
CD73 compounds
Granted: March 5, 2024
Patent Number:
11919869
Provided herein is A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.
